CTOs on the Move

Lumen Bioscience

www.lumen.bio

 
Lumen Bioscience develops oral antibody therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.lumen.bio
  • 1441 North 34th Street Suite 300
    Seattle, WA USA 98103
  • Phone: 206.899.1904

Executives

Name Title Contact Details

Funding

Lumen Bioscience raised $15.1M on 09/01/2020

Similar Companies

Mana Therapeutics

MANA was founded in November 2018, based on the research and human proof-of-concept clinical trials conducted by Dr. Catherine Bollard and her team at Children`s National Hospital (CNH) in Washington, D.C., along with colleagues at Johns Hopkins Medical Center.

BioScience Business Solutions

BioScience Business Solutions is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020

Cadence Neuroscience

Cadence Neuroscience is developing a next generation implantable device therapy for epilepsy. The therapy, pioneered by researchers at Mayo Clinic over the past decade, uses advanced methods to provide individualized treatment for each patient. Our core technology includes a specialized neuromodulation platform that enables these methods. Cadence is currently engaged in the engineering and testing of the platform, and preparing for additional clinical evaluations.

GenCanna

Founded by industry pioneers who championed the world`s leading hemp CBD genetics, formulations and spearheaded groundbreaking US hemp legislation, GenCanna ™ is focused on scaling our premium hemp genetics production for food products with easy availability locally, nationally and globally.